Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success
20-Sep-2023 -
Merck announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., ...
artificial intelligence
drug discovery
immunology
+2